Welldoc®, a prominent leader in AI-powered digital health innovation, has announced a significant collaboration to power the newly launched Lilly Health™ Personalized Health & Medicine Platform (Lilly Health app) using its advanced cardiometabolic digital health platform. This initiative aims to enhance the patient experience for individuals using Eli Lilly and Company’s incretin-based therapies for cardiometabolic conditions.

The Lilly Health app is specifically designed to provide tailored support for individuals prescribed Zepbound® (tirzepatide) or Mounjaro® (tirzepatide). These therapies are used for managing conditions such as obesity, type 2 diabetes, and moderate-to-severe obstructive sleep apnea associated with obesity. The collaboration between Lilly and Welldoc seeks to create a more seamless patient journey by offering comprehensive educational resources and targeted support mechanisms.

Key features of the Lilly Health app will include medication logging, reminders for medication adherence, connectivity with various health devices, and detailed health data tracking. These tools are intended to empower patients in managing their cardiometabolic health goals, including weight management, more effectively.

Kevin McRaith, President and CEO of Welldoc, expressed pride in expanding their work with Lilly, stating, “Welldoc's robust and AI-powered digital health platform is uniquely equipped to be a powerful foundation for the Lilly Health app. Our proven ability to integrate complex data, deliver personalized insights and support individuals across multiple cardiometabolic conditions positions us as the ideal technology partner for Lilly's ambitious vision. We are confident that our scalable and secure platform will enable Lilly Health to deliver a truly transformative and connected experience for patients.”

The Lilly Health app is built upon Welldoc’s well-established digital cardiometabolic platform. This platform offers users extensive device and data connectivity, in-app resources for nutrition and exercise, and comprehensive trends and insights. These features are designed to assist individuals in managing complex cardiometabolic conditions in consultation with their healthcare providers and to optimize their overall health over time.

Welldoc is recognized as a digital health leader revolutionizing cardiometabolic care by integrating personalized, real-time, and actionable insights into the daily lives of individuals. Their comprehensive platform provides AI-powered digital coaching across a spectrum of conditions including pre-diabetes, diabetes, hypertension, heart failure, and weight and obesity management, complemented by integrated mental wellbeing and sleep support. As an FDA-cleared digital health solution, Welldoc guides individuals through managing diabetes, enabling self-care and enhancing connections with their healthcare teams. The company collaborates with health plans, health systems, and employers to extend care, improve health outcomes, and reduce costs.

Welldoc’s impressive credentials include 11 FDA 510(k) clearances for diabetes functionality within its platform, an intellectual property portfolio of over 50 patents for its advanced AI and first-in-class technology, and more than 90 clinical publications, many of which highlight the value of combining Continuous Glucose Monitoring (CGM) with AI-powered digital health solutions. The company has been recognized with numerous accolades, including being named the “Best Overall Digital Health Company” by MedTech Breakthrough for two consecutive years and receiving the 2025 AI Excellence Awards, among others.

It is important to note that the Lilly Health™ Personalized Health & Medicine Platform is intended for use as a health management aid for adult patients aged 18 years or older who have been prescribed Zepbound® or Mounjaro®. The platform provides users with medication reminders, medication dose logging, and health data logging. However, Lilly Health is not intended to provide treatment decisions or replace the care and advice of a licensed Health Care Provider (HCP). All medical analysis and treatment plans should be performed by a licensed HCP.

Zepbound® (tirzepatide) is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who have weight-related medical problems, to lose excess body weight and keep it off. It is also indicated to help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity improve their OSA. Zepbound should be used with a reduced-calorie diet and increased physical activity. It contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. The safety and effectiveness of Zepbound in children are not known.

Mounjaro® (tirzepatide) is an injectable prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. It is not known if Mounjaro can be used in people who have had pancreatitis. Mounjaro is not for use in people with type 1 diabetes, and its safety and effectiveness in children under 18 years of age are not known.